PRIMAGEN AWARDED US PATENT FOR MITOCHONDRIAL DNA QUANTIFICATION

Primagen Holding BV, a molecular diagnostics company specialising in infectious disease and oncology, announced today that the US Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment. Mitox(tm) has potential applications as part of the treatment for highly active antiretroviral (HAART) HIV-1 treatment and other antiviral treatments using nucleoside analogues.
PR Newswire